OwnCompany Inc

Axonius, Inc is a cybersecurity company based in New York, NY that offers a comprehensive platform for asset management and policy enforcement. Their platform allows IT and security teams to gain a complete understanding of all digital infrastructure assets, their relationships, and business-level context, helping them mitigate threats, navigate risk, and automate action. With Axonius, customers can unify data from multiple sources, both on-premise and in the cloud, to reduce manual work and improve visibility. Their solutions cater to various industries, including energy, finance, healthcare, manufacturing, state and local government, education, retail, and technology. Axonius is trusted by customers for its ability to eliminate manual, repetitive tasks and provide actionable insights for informed decision-making.Generated from the website

Dataiku Inc is a leading AI and data science platform that empowers organizations to create and consume AI solutions. With its comprehensive capabilities in generative AI, data preparation, visualization, machine learning, and more, Dataiku offers a single platform designed for scalability and collaboration. By providing solutions tailored to various industries and departments, such as banking, manufacturing, marketing, and logistics, Dataiku enables businesses to accelerate their AI efforts and drive innovation. With a strong focus on collaboration, governance, and security, Dataiku is trusted by customers worldwide to transform data into actionable insights.Generated from the website

Owkin is an AI biotechnology company that aims to find personalized treatments for every patient by leveraging the power of artificial intelligence. Through their innovative approach, they identify new treatments, accelerate clinical trials, and develop diagnostic tools by integrating human and artificial intelligence. With a focus on protecting patient privacy and securing proprietary data, Owkin uses federated data access to unlock valuable insights from patient data. Founded in 2016 by Thomas Clozel MD, a former assistant professor in clinical onco-hematology, and Gilles Wainrib, a pioneer in machine learning in biology, Owkin has raised over $300 million in funding and has become a unicorn in the industry. Their team of experts collaborates with leading biopharma companies and academic researchers to address the challenges in biopharma research and improve the understanding of disease mechanics. With offices in multiple locations including Paris, New York, and London, Owkin is at the forefront of revolutionizing precision medicine.Generated from the website